Home Featured Page 112

Featured

Latest

Weekly Psychedelic Policy Briefing: October 12, 2026

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

atai Life Sciences to Participate in Upcoming June Investor Conferences

BREAKING: State of Kentucky Sets aside $42 Million for Psychedelic Research,...

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office...

COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation...

Psychedelic Bulletin #138: Delix’s Non-Hallucinogenic Psychedelic Enters the Clinic; Arizona Earmarks...

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

PT412 – Psychedelics and Virtual Reality: Where Novel Experience, Technology, and...

Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part...

FILAMENT HEALTH ANNOUNCES INTERIM RESULTS FROM PHASE I CLINICAL TRIAL AT...

COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference

EDITOR PICKS

Weekly Psychedelic Policy Briefing: October 12, 2026

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Weekly Psychedelic Policy Briefing: October 12, 2026

How to Change Your Behavior

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

atai Life Sciences to Participate in Upcoming June Investor Conferences

BREAKING: State of Kentucky Sets aside $42 Million for Psychedelic Research,...

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office...

COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation...

Psychedelic Bulletin #138: Delix’s Non-Hallucinogenic Psychedelic Enters the Clinic; Arizona Earmarks...

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

PT412 – Psychedelics and Virtual Reality: Where Novel Experience, Technology, and...

Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part...

FILAMENT HEALTH ANNOUNCES INTERIM RESULTS FROM PHASE I CLINICAL TRIAL AT...

COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference

EDITOR PICKS

Weekly Psychedelic Policy Briefing: October 12, 2026

How to Change Your Behavior

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY